Continued Progress in Technology Readiness for AI Datacom Market
Executed Purchase Agreement With Aixtron for MOCVD Capacity Expansion and Large-Diameter Wafer Manufacturing
Fiscal First Quarter 2027 and Subsequent Highlights
- Increased Technology Readiness: Advanced development of high-speed photodetectors and quantum dot lasers leveraging capabilities at
Aeluma and supply chain partners such as Sumitomo Chemical Advanced Technologies. - Manufacturing Expansion: Finalized a purchase agreement with Aixtron for a new 200 mm capable MOCVD system to expand manufacturing capacity and accelerate development for non-indium-phosphide photonics.
- Customer Engagements: Expanded customer discussions in Datacom and other markets regarding product opportunities and non-recurring engineering investments. Several initiatives involve potentially high-volume demand to support the 2028 through 2032 AI infrastructure buildout.
- CHIPS Funding: Continued diligence and definitive agreement negotiations with the
U.S. Department of Commerce CHIPS R&D Office for up to$30 million in proposed funding for development and commercialization of photonics for AI and Advanced Computing.
Management Commentary
“The current
“Demand for photonic components includes lasers, modulators, photodetectors, and photonic integrated circuits or PICs. Supply chains are constrained, including indium phosphide substrate production and wafer fab capacity. Adopting proven strategies from consumer markets, Aeluma’s technology instead leverages gallium arsenide or silicon substrates, and existing fabs that are already qualified for large-volume markets.”
“As we progress through fiscal 2027, we remain focused on technology and product development for AI Datacom opportunities. Aeluma’s high-speed photodetectors and quantum dot lasers continue to attract customer attention. Our efforts include working with supply chain partners such as Sumitomo Chemical Advanced Technologies to ready technology in a production environment, and investment in MOCVD manufacturing capacity. Lastly, we continue to expand our customer discussions including negotiations on potential development investments and potentially large-volume product opportunities.”
Fiscal First Quarter 2027 Financial Results
- Revenue was
$0.6 million , compared with$1.4 million in the first quarter of fiscal 2026, generated primarily from R&D contracts. - Net loss was
$3.8 million , or ($0.19 ) per basic and diluted share, compared with a net loss of$1.5 million , or ($0.09 ) per basic and diluted share, for the same period last year. - Adjusted EBITDA loss was
$2.7 million , compared with an adjusted EBITDA loss of$0.4 million in the same period last year. - Cash and cash equivalents totaled
$53.9 million atSeptember 30, 2026 , compared with$56.0 million atJune 30, 2026 .
Conference Call and Webcast
A live webcast of the call will also be available on the “Investors” section of Aeluma’s website. The live webcast can also be accessed by clicking here. A replay of the conference call will be available on Aeluma’s website shortly after the call concludes.
Annual Meeting of Stockholders
Aeluma’s 2026 Annual Meeting of Stockholders will be held virtually on
Note about Non-GAAP Financial Measures
This press release includes and makes reference to certain non-GAAP financial measures. The presentation of this financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP.
This press release includes non-GAAP financial measures, including:
- Non-GAAP net income (loss), which is defined as GAAP net income (loss) plus stock-based compensation expenses; and
- Adjusted EBITDA, defined as non-GAAP net income (loss) plus depreciation and amortization expenses, less interest income.
A reconciliation between GAAP and non-GAAP financial results is provided in the financial statements portion of this press release.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company's expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors. These statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
About
Company:
(805) 351-2707
info@aeluma.com
Investor Contact:
Financial
(310) 622-8220
ir@aeluma.com
Condensed Consolidated Balance Sheets | ||||||||
| ($ in thousands) | 2026 (unaudited) | 2026 | ||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 53,875 | $ | 56,006 | ||||
| Accounts receivable | 504 | 340 | ||||||
| Prepaids and other current assets | 716 | 965 | ||||||
| Total current assets | 55,095 | 57,311 | ||||||
| Property and equipment: | ||||||||
| Equipment | 2,590 | 2,338 | ||||||
| Leasehold improvements | 547 | 547 | ||||||
| Accumulated depreciation | (1,598 | ) | (1,469 | ) | ||||
| Property and equipment, net | 1,539 | 1,416 | ||||||
| Right-of-use asset - operating | 1,868 | 1,916 | ||||||
| Other assets | 21 | 21 | ||||||
| Total assets | $ | 58,523 | $ | 60,664 | ||||
| Liabilities and stockholders' equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 368 | $ | 341 | ||||
| Accrued expenses and other current liabilities | 1,502 | 1,369 | ||||||
| Lease liability - operating, current portion | 183 | 180 | ||||||
| Total current liabilities | 2,053 | 1,890 | ||||||
| Lease liability - operating, long-term portion | 1,795 | 1,842 | ||||||
| Total liabilities | 3,848 | 3,732 | ||||||
| Commitments and contingencies | - | - | ||||||
| Stockholders’ equity: | ||||||||
| Preferred stock | - | - | ||||||
| Common stock | 2 | 2 | ||||||
| Additional paid-in capital | 84,234 | 82,735 | ||||||
| Accumulated deficit | (29,561 | ) | (25,805 | ) | ||||
| Total stockholders’ equity | 54,675 | 56,932 | ||||||
| Total liabilities and stockholders’ equity | $ | 58,523 | $ | 60,664 | ||||
Condensed Consolidated Statements of Operations (unaudited) | ||||||||||||
| Three Months Ended | ||||||||||||
| ($ in thousands, except per share data) | 2026 | 2026 | 2025 | |||||||||
| Revenue | $ | 568 | $ | 582 | $ | 1,385 | ||||||
| Operating expenses: | ||||||||||||
| Cost of revenue | 339 | 433 | 701 | |||||||||
| Research and development | 2,274 | 606 | ||||||||||
| General and administrative | 1,952 | 2,247 | 1,686 | |||||||||
| Total operating expenses | 4,816 | 4,954 | 2,993 | |||||||||
| Loss from operations | (4,248 | ) | (4,372 | ) | (1,608 | ) | ||||||
| Other income: | ||||||||||||
| Interest income | 492 | 359 | 115 | |||||||||
| Total other income | 492 | 359 | 115 | |||||||||
| Loss before income tax expense | (3,756 | ) | (4,013 | ) | (1,493 | ) | ||||||
| Income tax expense | - | - | - | |||||||||
| Net loss | $ | (3,756 | ) | $ | (4,013 | ) | $ | (1,493 | ) | |||
| Net loss per share – basic and diluted | $ | (0.19 | ) | $ | (0.22 | ) | $ | (0.09 | ) | |||
| Weighted average common shares outstanding - basic and diluted | 19,270,622 | 18,603,331 | 16,141,153 | |||||||||
| Book value per share | $ | 2.84 | $ | 3.06 | $ | 2.53 | ||||||
Condensed Consolidated Statements of Cash Flows (unaudited) | ||||||||
| Three Months Ended | ||||||||
| ($ in thousands) | 2026 | 2025 | ||||||
| Operating activities: | ||||||||
| Net loss | $ | (3,756 | ) | $ | (1,493 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Stock-based compensation expense | 1,376 | 1,056 | ||||||
| Depreciation and amortization expense | 130 | 102 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (164 | ) | (286 | ) | ||||
| Prepaids and other current assets | 249 | (196 | ) | |||||
| Other assets | (1 | ) | (8 | ) | ||||
| Accounts payable | 27 | (88 | ) | |||||
| Accrued expenses and other current liabilities | 393 | 98 | ||||||
| Net cash used in operating activities | (1,746 | ) | (815 | ) | ||||
| Investing activities: | ||||||||
| Purchase of equipment | (252 | ) | (210 | ) | ||||
| Net cash used in investing activities | (252 | ) | (210 | ) | ||||
| Financing activities: | ||||||||
| Proceeds from stock option exercise | 174 | 47 | ||||||
| Proceeds from public offering, net of offering costs | - | 23,385 | ||||||
| Payment for taxes related to net share settlement of stock options and restricted stock units | (307 | ) | - | |||||
| Net cash provided by (used in) financing activities | (133 | ) | 23,432 | |||||
| Net change in cash and cash equivalents | (2,131 | ) | 22,407 | |||||
| Cash and cash equivalents, beginning of period | 56,006 | 15,740 | ||||||
| Cash and cash equivalents, end of period | $ | 53,875 | $ | 38,147 | ||||
| Supplemental non-cash disclosures: | ||||||||
| Right-of-use asset - operating obtained in exchange for lease liability - operating | $ | - | $ | 274 | ||||
Reconciliation of GAAP and Non-GAAP Financial Measures (unaudited) | ||||||||||||
| Three Months Ended | ||||||||||||
| ($ in thousands, except per share data) | 2026 | 2026 | 2025 | |||||||||
| GAAP net loss | $ | (3,756 | ) | $ | (4,013 | ) | $ | (1,493 | ) | |||
| Non-GAAP adjustments: | ||||||||||||
| Stock-based compensation | 1,376 | 1,308 | 1,056 | |||||||||
| Total adjustments to GAAP net loss | 1,376 | 1,308 | 1,056 | |||||||||
| Non-GAAP net loss | $ | (2,380 | ) | $ | (2,705 | ) | $ | (437 | ) | |||
| Depreciation & amortization | 130 | 126 | 102 | |||||||||
| Interest income | (492 | ) | (359 | ) | (115 | ) | ||||||
| Adjusted EBITDA | $ | (2,742 | ) | $ | (2,938 | ) | $ | (450 | ) | |||
| GAAP net loss per share – basic and diluted | $ | (0.19 | ) | $ | (0.22 | ) | $ | (0.09 | ) | |||
| Non-GAAP adjustments | 0.07 | 0.07 | 0.06 | |||||||||
| Non-GAAP net loss per share – basic and diluted | $ | (0.12 | ) | $ | (0.15 | ) | $ | (0.03 | ) | |||
Source: 